Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Immune Design CS (IMDZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 282,935
  • Shares Outstanding, K 48,365
  • Annual Sales, $ 2,200 K
  • Annual Income, $ -54,760 K
  • 60-Month Beta 3.48
  • Price/Sales 128.84
  • Price/Cash Flow N/A
  • Price/Book 3.06
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.86
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/01/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.28
  • Number of Estimates 1
  • High Estimate -0.28
  • Low Estimate -0.28
  • Prior Year -0.28
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.82 +0.52%
on 03/14/19
5.85 unch
on 04/01/19
+0.02 (+0.34%)
since 03/01/19
3-Month
1.22 +379.51%
on 01/03/19
5.85 unch
on 04/01/19
+4.55 (+350.00%)
since 12/31/18
52-Week
1.10 +431.82%
on 12/24/18
5.85 unch
on 04/01/19
+2.55 (+77.27%)
since 03/29/18

Most Recent Stories

More News
Merck Completes Tender Offer to Acquire Immune Design

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares...

MRK : 74.73 (+0.17%)
IMDZ : 5.85 (unch)
Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating the Boards of Directors of Civitas, Entegra, and Immune Design on Behalf of Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Civitas Solutions, Inc., Entegra Financial Corp., and Immune Design Corp. Additional...

CIVI : 17.76 (+0.11%)
ENFC : 29.50 (+24.74%)
IMDZ : 5.85 (unch)
IMMUNE DESIGN CORP. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Merger

Rigrodsky & Long, P.A.:

MRK : 74.73 (+0.17%)
IMDZ : 5.85 (unch)
INVESTOR ALERT: Monteverde & Associates PC is Investigating the Recently Announced Acquisition

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating:

ELLI : 98.99 (unch)
MXWL : 4.29 (-1.83%)
CASM : 2.45 (+0.41%)
IMDZ : 5.85 (unch)
STI : 63.82 (+0.44%)
ULTI : 330.85 (-0.05%)
LABL : 49.97 (-0.06%)
Merck Begins Tender Offer to Acquire Immune Design

Merck (NYSE: MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of...

MRK : 74.73 (+0.17%)
IMDZ : 5.85 (unch)
INVESTOR ALERT: Monteverde & Associates PC is Investigating the Recently Announced Acquisition

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating:

ELLI : 98.99 (unch)
MXWL : 4.29 (-1.83%)
CASM : 2.45 (+0.41%)
IMDZ : 5.85 (unch)
STI : 63.82 (+0.44%)
ULTI : 330.85 (-0.05%)
LABL : 49.97 (-0.06%)
The Zacks Analyst Blog Highlights: Merck, Design, Roche and AbbVie

The Zacks Analyst Blog Highlights: Merck, Design, Roche and AbbVie

MRK : 74.73 (+0.17%)
IMDZ : 5.85 (unch)
ABBV : 78.67 (+0.01%)
RHHBY : 32.7700 (-0.36%)
Merck to Buy Immunotherapy Developer Immune Design for $300M

Merck (MRK) plans to acquire Immune Design for $300 million in cash. Merck will pay $5.85 in cash for each share of Immune Design.

MRK : 74.73 (+0.17%)
LLY : 118.00 (+0.43%)
IMDZ : 5.85 (unch)
BMY : 44.62 (-1.54%)
Thinking about buying stock in Apple, Canopy Growth Corp, Immune Design, Roku Inc or Zosano Pharma?

InvestorsObserver issues critical PriceWatch Alerts for AAPL, CGC, IMDZ, ROKU, and ZSAN.

ROKU : 60.97 (-0.91%)
AAPL : 207.16 (-0.15%)
IMDZ : 5.85 (unch)
ZSAN : 3.96 (-0.25%)
Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates

Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).

NVO : 48.37 (-0.60%)
MRK : 74.73 (+0.17%)
LLY : 118.00 (+0.43%)
IMDZ : 5.85 (unch)
ABBV : 78.67 (+0.01%)
RHHBY : 32.7700 (-0.36%)
PFE : 39.37 (-0.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade IMDZ with:

Business Summary

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on the development of immune-based therapies based on its DCVex (TM) and GLAAS (TM) discovery platforms for cancer and other chronic conditions. Its product candidates in Phase I clinical trials comprise LV305, CMB305,...

See More

Key Turning Points

2nd Resistance Point 5.86
1st Resistance Point 5.85
Last Price 5.85
1st Support Level 5.84
2nd Support Level 5.84

See More

52-Week High 5.85
Last Price 5.85
Fibonacci 61.8% 4.04
Fibonacci 50% 3.47
Fibonacci 38.2% 2.91
52-Week Low 1.10

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar